drugset / Trial / NCT04232644
Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a pilot randomized, double-blind, active-controlled, 2-treatment, crossover study to evaluate the PK, user experience and abuse liability of manipulated ADAIR compared to a manipulated commercially-available d-amphetamine sulfate IR formulation administered intranasally in non-dependent recreational stimulant users. The study is comprised of 4 phases: Screening, Qualification, Treatment, and Follow-up/Early Termination.
Timeline
- Start
- 2019-05-27
- Primary completion
- 2019-07-17
- Completion
- 2019-07-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADAIR | Unknown | 30 mg | Intranasal |
| Subject | Dextroamphetamine | Small molecule | 30 mg | Intranasal |